14Jan/14

Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 – Update – NASDAQ

Monoclonal Anti-CD20 Antibodies

Drug Discovery & Development

Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 – Update
NASDAQ
… change the primary endpoint of the Phase 3 PIX-R, or PIX306, post-marketing commitment study of pixantrone-rituximab versus gemcitabine-rituximab for patients with relapsed B-cell non-Hodgkin lymphoma from overall survival to progression-free survival.
Cell Therapeutics reaquire rights to two anti-cancer compounds from Novartispharmabiz.com
Cell Therapeutics Inc.: Cell Therapeutics Announces 2014 Outlook and Recent …The Wall Street Transcript

all 31 news articles »
13Jan/14

Portola Pharmaceuticals Inc (PTLA): Portola Pharmaceuticals' CEO Presents at … – Seeking Alpha

Monoclonal Anti-CD20 Antibodies

Portola Pharmaceuticals Inc (PTLA): Portola Pharmaceuticals’ CEO Presents at …
Seeking Alpha
Targeting not only B cell signaling but cytokine signaling via JAK we think is potential beneficial for patients that are not addressed by the other agents including Ibrutinib PI3 kinase inhibitors, rituximab. We have an ongoing, as I said, Phase I/II …

and more »
13Jan/14

FDA Accepts NDA for Gilead Lymphoma Drug – Drug Discovery & Development

Monoclonal Anti-CD20 Antibodies

Drug Discovery & Development

FDA Accepts NDA for Gilead Lymphoma Drug
Drug Discovery & Development
11, 2013, was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Following Gilead’s NDA submission for …
US FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment …Investor’s Business Daily

all 10 news articles »
13Jan/14

US FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment … – Investor's Business Daily

Monoclonal Anti-CD20 Antibodies

Drug Discovery & Development

US FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment …
Investor’s Business Daily
The NDA for iNHL, submitted on September 11, 2013, was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.
FDA Accepts NDA for Gilead Lymphoma DrugDrug Discovery & Development

all 6 news articles »